Clinical characteristics, prognosis, and treatment of pelvic cryptorchid seminoma

Li, Yexiong; Coucke, Philippe; Qian, Tu-Nan; Huang, Yuesheng; Gu, Dayong; Mirimanoff, René-Olivier; Yu, Zi-Hao

doi:10.1016/s0360-3016(97)00052-7

Cited by 7 publications

(7 citation statements)

References 33 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The size of primary tumor in inguinal seminoma is similar to that found in scrotal seminoma, but it is much smaller than that seen in pelvic cryptorchid seminoma (22). This can easily be explained by early detection and diagnosis of tumor development in case of inguinal and scrotal seminoma.…”

Section: Discussion Presentationmentioning

confidence: 64%

“…Of these 373 patients, 136 had a history of cryptorchidism, of whom 25 (23 inguinal and 2 pelvic) had prior orchiopexy. Sixtyeight patients with seminomas arising in pelvic undescended cryptorchid testis were reported elsewhere (22). Of the remaining 66 patients, 43 patients had primary tumor located distally or proximally in the inguinal canal, and 23 patients who underwent prior orchiopexy for inguinal cryptorchidism presented with primary tumor in the scrotum.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Seminoma arising in corrected and uncorrected inguinal cryptorchidism: Treatment and prognosis in 66 patients

Coucke

Qian

et al. 1997

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Purpose: The purpose of this study was to analyze prognosis and treatment results for seminoma arising in corrected and uncorrected inguinal cryptorchidism (SCIC and SUIC). Methods and Materials: We reviewed 66 patients with inguinal seminomas between June 1958 and December 1991 at the Cancer Hospital and Institute of Chinese Academy of Medical Sciences. Of these patients, 23 had prior orchiopexy and 43 presented with an inguinal form of cryptorchidism. At presentation, 17 of 66 (26%) patients had nodal metastases. This nodal involvement was 30% (7 of 23) for SCIC and 23% (10 of 43) for SUIC, respectively. These numbers are comparable with those in a series of patients treated for scrotal seminoma at our institution (26% vs. 20%). However, 3 of 23 (13%) patients who had prior orchiopexy presented with inguinal nodal metastasis as compared with 0 of 43 patients with SUIC or 4 of 237 patients with scrotal seminoma (p < .05). There were 49 stage I, 5 stage IIA, 8 stage IIB, 3 stage III, and 1 stage IV patients. All patients underwent radical orchiectomy and received further radiotherapy, chemotherapy, or both. Patients with stage I and stage II disease were treated primarily with radiotherapy, whereas patients with stage III and IV disease were treated with chemotherapy. Results: The overall and disease-free survival at 5 and 10 years was 94% and 92%, 89% and 87%, respectively. The overall 5-and lo-year survival by stage was 100% and 100% for stage I, and 77% and 68% for stage II, respectively @ < .05). There was no significant difference in survival between SUIC and SCIC (93% vs. 96% at 5 years). Four patients developed relapse. Two of these four patients experienced relapse at the inguinal area, due to a marginal miss. Three of four patients with relapse were successfully salvaged, and one died of disease. Conclusion: Our results indicate that prognosis for inguinal seminoma is excellent and similar to that of scrotal seminoma. Postorchiectomy radiotherapy can be considered as the standard treatment for stage I and IIA inguinal seminoma. We recommend routinely including the para-aortic and ipsilateral pelvic nodes. 0 1997 Elsevier Science Inc. Seminoma, Cryptorchidism, Radiotherapy.

show abstract

Section: Discussion Presentationmentioning

confidence: 64%

Section: Introductionmentioning

confidence: 99%

Seminoma arising in corrected and uncorrected inguinal cryptorchidism: Treatment and prognosis in 66 patients

Coucke

Qian

et al. 1997

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cause of neutropenia, leukopenia is the result of side effects of etoposide and cisplatin which causes bone marrow myelosuppression so that the production of white blood cells and platelets decreases. (Li et al, 1997) Alopecia is the most common side effect due to bleomycin and etoposide, this is due to chemotherapy drugs causing disruption of cellular absorption of hair follicles thus disrupting hair growth (J.A Christian ett all., 2003).…”

Section: Resultsmentioning

confidence: 99%

Correlations Between Staging and Chemotheraphy Response with Testicular Carcinoma Non-Seminoma at Dr. Soetomo Hospital, Surabaya, Indonesia

Nugroho

Renaldo

Djatisoesanto

2020

FMI

View full text Add to dashboard Cite

The purpose of this study was to describe patients’ characteristics, correlation between staging non-seminoma cancer and chemotherapy response. Data on age, location of tumor, staging, serum levels of the tumor marker post operative, adjuvant therapy, chemotherapy side effects, and response of patient to chemotherapy were gained from medical records in Soetomo Hospital Surabaya from January 2012 to December 2015, and analyzed with SPSS. Correlation between staging and chemotherapy response, correlation primary tumor staging (pT) and Metastasis (M), correlation regional lymph nodes staging (N) and metastasis (M), correlation serum tumor marker and chemotherapy response was proccessed by Spearman correlation test. There were no significant correlation between pT staging and M and no significant correlation between N and M staging. Based on tumor markers (S), mostly patients were S2. There were no significant correlation between the response to chemotherapy and serum tumor marker levels. In category of staging group, the most are 14 patients stage III. BEP was the most adjuvant Chemotherapy. Nausea and vomiting were The most complained during chemotherapy. Anemia were the most hematologic side effects of chemotherapy. There are no significant correlation between the staging of non-seminoma and the response to chemotherapy. Conclusion: Non seminoma mostly happened in young males. Non-seminoma responses to chemotherapy. Patients in early stage would give a good response to chemotherapy compared to those with advanced stage. After chemotherapy, evaluation should be done to the patients' complaints and complete blood count to detect side effects.

show abstract

“…Twenty-percent of patients have involvement of regional lymph nodes at presentation (Any T, N1-3, M0: Stage II), most commonly para-aortic nodes. Involvement of inguinal and iliac lymph nodes is uncommon except in cases of prior pelvic or abdominal surgery where the normal lymphatic drainage may be disturbed, seminoma arising in a cryptorchid testis [4,5], congenital anomalies of the genitourinary tract [6], or bulky para-aortic lymphadenopathy [6]. Distant metastases are evident at diagnosis (Any T, Any N, M1: Stage III) in only 5% of patients.…”

Section: Primary Surgery and Staging Of Testicular Seminomamentioning

confidence: 99%

Management of testicular seminoma

1999

View full text Add to dashboard Cite

Testicular seminoma is highly curable with currently available treatments. Today, there is good evidence that patients with Stage I disease can be treated equally well with either immediate adjuvant para‐aortic and ipsilateral pelvic radiotherapy or close surveillance with treatment at the time of relapse. The decision as to which of these management strategies is adopted in an individual case is a complex function of physician preference, and the emotional, social, and economic circumstances of the patient. Ongoing research in Stage I seminoma is focused at reducing the side‐effects of treatment either by modifying the radiation treatment plan or by using adjuvant chemotherapy in lieu of radiation. Stage II patients with small bulk retroperitoneal lymphadenopathy have a high probability of long‐term disease control with radiotherapy. Patients with bulky Stage II disease or Stage III disease should be treated with cisplatin‐based chemotherapy. Semin. Surg. Oncol. 17:240–249, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

Clinical characteristics, prognosis, and treatment of pelvic cryptorchid seminoma

Cited by 7 publications

References 33 publications

Seminoma arising in corrected and uncorrected inguinal cryptorchidism: Treatment and prognosis in 66 patients

Seminoma arising in corrected and uncorrected inguinal cryptorchidism: Treatment and prognosis in 66 patients

Correlations Between Staging and Chemotheraphy Response with Testicular Carcinoma Non-Seminoma at Dr. Soetomo Hospital, Surabaya, Indonesia

Management of testicular seminoma

Contact Info

Product

Resources

About